2023
Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020
Dhingra L, Aminorroaya A, Oikonomou E, Nargesi A, Wilson F, Krumholz H, Khera R. Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020. JAMA Network Open 2023, 6: e2316634. PMID: 37285157, PMCID: PMC10248745, DOI: 10.1001/jamanetworkopen.2023.16634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCardiovascular DiseasesCross-Sectional StudiesFemaleHumansHypertensionMaleMiddle AgedObesityRisk FactorsConceptsHealth Information National Trends SurveyUS adultsExacerbate disparitiesWearable device usersCardiovascular diseaseCardiovascular healthPopulation-based cross-sectional studySelf-reported cardiovascular diseaseCardiovascular disease risk factorsNational Trends SurveyOverall US adult populationCardiovascular risk factor profileSelf-reported accessAssociated with lower useUse of wearable devicesImprove cardiovascular healthLower household incomeLower educational attainmentUS adult populationRisk factor profileNationally representative sampleCross-sectional studyProportion of adultsTrends SurveyWearable device data
2022
Wearables in Cardiovascular Disease
Kumar S, Victoria-Castro AM, Melchinger H, O’Connor K, Psotka M, Desai NR, Ahmad T, Wilson FP. Wearables in Cardiovascular Disease. Journal Of Cardiovascular Translational Research 2022, 16: 557-568. PMID: 36085432, DOI: 10.1007/s12265-022-10314-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatients
2020
Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer
Angraal S, Caraballo C, Kahn P, Bhatnagar A, Singh B, Wilson FP, Fiuzat M, O'Connor CM, Allen LA, Desai NR, Mamtani R, Ahmad T. Geographical affiliation with top 10 NIH-funded academic medical centers and differences between mortality from cardiovascular disease and cancer. American Heart Journal 2020, 230: 54-58. PMID: 32950462, PMCID: PMC7734611, DOI: 10.1016/j.ahj.2020.08.014.Peer-Reviewed Original ResearchConceptsCardiovascular mortality ratesMortality rateCardiovascular mortalityCancer mortalityCardiovascular diseaseMedical CenterIndex groupAnnual cardiovascular mortality rateCardiovascular mortality trendsCancer mortality ratesAcademic medical centerBenefit of patientsMortality trendsSociodemographic characteristicsMortalityIncremental benefitComparison groupNIH fundingImplementation scienceNIHHigh rateDiseaseRapid translationAverage declineResearch priorities
2019
Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study
Schrauben SJ, Jepson C, Hsu JY, Wilson FP, Zhang X, Lash JP, Robinson BM, Townsend RR, Chen J, Fogelfeld L, Kao P, Landis JR, Rader DJ, Hamm LL, Anderson AH, Feldman HI. Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study. BMC Nephrology 2019, 20: 60. PMID: 30786864, PMCID: PMC6383235, DOI: 10.1186/s12882-019-1220-6.Peer-Reviewed Original ResearchConceptsChronic kidney disease progressionKidney disease progressionCardiovascular eventsHOMA-IRInsulin resistanceCKD progressionCause mortalityDisease progressionChronic Renal Insufficiency Cohort study participantsChronic Renal Insufficiency Cohort (CRIC) StudyCox proportional hazards modelAbsence of diabetesCohort Study participantsHomeostasis model assessmentProportional hazards modelPositive associationBackgroundInsulin resistanceCKD complicationsCardiovascular endpointsCohort studyHemoglobin A1cMetabolic syndromeKidney diseaseC-peptideHazards model